What did Rua Bioscience Limited announce?
Rua Bioscience Limited (NZX: RUA) filed “Rua announces detail of rights offer” with NZX on 22 September 2026, as a listing change announcement.
From the announcement:“Capital raise – Pro-rata renounceable Rights Offer Rua is today announcing an offer to existing shareholders an opportunity to participate in our renoucenable rights issue of 1 New Shares for every 3 Existing Shares to raise up to $2.8million (“ Rights Offer”).”
- Which company?
- Rua Bioscience Limited (NZX: RUA)
- When was it filed?
- 22 September 2026
- Where is the original?
- NZX announcement
Rua announces detail of rights offer
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
FOR PUBLIC RELEASE
NZX Limited
Wellington
22 September 2026
Capital raise – Pro-rata renounceable Rights Offer
Rua is today announcing an offer to existing shareholders an opportunity to participate in
our renoucenable rights issue of 1 New Shares for every 3 Existing Shares to raise up to
$2.8million (“
Rights Offer”).
FY26 marked an important period of meaningful commercial progress for Rua. Our export-
led strategy is delivering tangible results, with revenue increasing to $2.9 million, compared
with $1.9 million in FY25, alongside continued expansion across our key international
markets. We have strengthened our position in established markets and opened important
new growth pathways, demonstrating the increasing international demand for high-
quality New Zealand-grown medicinal cannabis.
Most significantly, towards the end of FY26, Rua secured its largest export agreement to
date, signing a major UK sales and distribution agreement with one of the world’s leading
medical cannabis companies. Expected to generate an estimated NZ$10 million in revenue
over its initial two-year term.
OFFER ANNOUNCEMENT
$0.3m
$1.9m
$2.9m
FY24FY25FY26
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
This new export agreement represents more than a future opportunity. It is an important
commercial validation of the strategy Rua has been pursuing: building an export-led
business founded on differentiated New Zealand genetics, high-quality cultivation and
access to established international markets.
The next phase for Rua is to convert this commercial momentum into sustained revenue
growth. Doing so requires investment in inventory and working capital to meet increasing
customer demand. The capital sought through this Offer will therefore primarily support
the fulfilment of customer demand and the conversion of available market opportunities
into revenue and margin, enabling Rua to maximise the value of the opportunities now
available to it.
Rua intends to use the cash raised through the Rights Offer to fund working capital and
marketing activities to support our growth opportunities, particularly in the United
Kingdom, alongside our other key international markets of Germany, Australia, Czechia
and Canada.
If fully subscribed, the Rights Offer, together with the expected proceeds from the sale of
the Gisborne manufacturing facility, is expected to provide the funding required to take
the business to a self-sustaining position.
The issue price under the Rights Offer is $0.025 per share, representing a 32 % discount to
the 20-day volume weighted average price of Rua shares up to 17 September 2026. Rua
notes that this price reflects that the Rights Offer is being offered to existing eligible
shareholders resident in New Zealand or Australia.
Eligible shareholders who take up their rights in full may also apply for any number of
additional shares at the same issue price under the Oversubscription Facility.
The key dates for the Rights Offer are as follows:
Announcement of the Offer Tu e s d a y, 2 2 September 2026
Rights Trading Opens Monday, 2 8 September 2026
Record Date 5pm, Tu e s d a y, 2 9 September 2026
Opening Date of the Offer 2pm, Wednesday, 30 September 2026
Rights Trading Closes Friday, 9 October 2026
Closing Date of the Offer Thursday, 15 October 2026
Announcement of Results of the Offer Tu e s d a y, 2 0 October 2026
Issue Date Wednesday, 21 October 2026
Quotation of New Shares on NZX Main
Board
Wednesday, 21 October 2026
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
Further Information
Rua has lodged an Investor Presentation and Offer Document with the NZX today. Both
documents contain important information including the terms of the Rights Offer and key
risk factors and Rua encourages shareholders to read them in full. The Offer Document
and Investor Presentation along with other important information relating to the Rights
Offer will be available on the website established for the Rights Offer at
www.shareoffer.co.nz/rua.
Shareholders with any questions about the Rights Offer, please email
rua@computershare.co.nz or call the Computershare Investor Information Line between
8:30am to 5.00pm Monday to Friday (NZDT) (excluding public holidays):
For New Zealand shareholders
0800 650 034 - toll free within New Zealand
+64 9 488 8793
For Australian shareholders
1800 501 366 - toll free within Australia
+61 3 9415 4083
Or alternatively, contact your broker or your financial, investment or other professional
adviser.
A copy of the following documents also accompany this announcement:
• Offer Document
• Investor Presentation
• Corporate Action Notice
• Cleansing Notice
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154
---
Rua Bioscience Limited
Renounceable Rights Offer
Offer Document
1 for 3 renounceable rights offer of ordinary shares
Dated 22 September 2026
Not for release to U.S. wire services or distribution in the United States.
This is an important document. You should read the whole document before deciding what action to take with your
Rights. If you have any doubts as to what you should do, please consult your broker, financial, investment, legal or other
professional advisor. This document may not be distributed outside New Zealand or Australia.
Important Information
General information
This document has been prepared by Rua Bioscience
Limited (“Rua”) in connection with a 1 for 3 renounceable
rights offer of New Shares to Eligible Shareholders
(“Offer”). The Offer is made under the exclusion in clause
19 of Schedule 1 of the Financial Markets Conduct Act
2013 (the “FMCA”).
This document is not a product disclosure statement for
the purposes of the FMCA and does not contain all of the
information that an investor would find in a product
disclosure statement, or which may be required in order
to make an informed investment decision about the Offer
or Rua.
Further Important Information
A presentation providing further important information in
relation to Rua and the Offer has been published by Rua
on 22 September 2026 (the “Investor Presentation”). A
copy of the Investor Presentation and other important
information released on 22 September 2026, as well as
other publicly available information referred to in this
document, are available at www.nzx.com under the ticker
code “RUA”.
The Investor Presentation includes details of the rationale
for the Offer. It also provides a general trading update and
explains in more detail the expected impact of the Offer,
including a non-exhaustive summary of certain key risks
associated with Rua and the Offer.
You should read the Investor Presentation in full, as it
contains important information to assist you in making an
investment decision in respect of the Offer. In particular,
you should read and consider Appendix B of the Investor
Presentation detailing the risks before making an
investment decision.
Additional information available
Rua is subject to continuous disclosure obligations under
the NZX Main Board Listing Rules. Further information
relating to the Offer can also be found in Rua’s recent
market announcements and its most recent audited
consolidated financial statements for the 12 month
period ended 30 June 2026, which can be found in Rua’s
2026 Annual Report which is accessible online at
www.nzx.com under the ticker code RUA and on Rua’s
website at https://www.ruabio.com/investors.
Rua may, during the period of the Offer, make additional
releases to the NZX. To the maximum extent permitted by
law, no release by Rua to the NZX will permit an applicant
under the Offer to withdraw any previously submitted
application without Rua’s prior consent.
We encourage you to read this document and to seek
investment advice from a suitably qualified professional
adviser before you consider investing.
Offering restrictions
No action has been taken to permit a public offering of
the New Shares in any jurisdiction outside New Zealand,
or Australia. The Offer may also be made and accepted in
such other place where a Shareholder satisfies Rua that
the Offer can lawfully be made and accepted in that
place.
However, Shareholders in the United States are not
eligible to participate in the Offer. Similarly, Shareholders
(including trustees, Custodians and nominees) who hold
Shares on behalf of persons in the United States, or who
are acting for the account or benefit of persons in the
United States, are not eligible to participate in the Offer
on behalf of those persons.
The distribution of this document (including an electronic
copy) in a jurisdiction outside the Offer Jurisdictions may
be restricted by law, and persons who come into
possession of it (including trustees, Custodians or
nominees) should seek advice on and observe any such
restrictions. In particular, no person may subscribe for,
purchase, offer, sell, distribute or deliver New Shares, or
be in possession of, or distribute to any other person, any
offering material or any documents in connection with the
Offer or the New Shares, in any jurisdiction unless in
compliance with all applicable laws and regulations.
The New Shares to be offered and sold under this Offer
have not been, and will not be, registered under the U.S.
Securities Act of 1933, as amended (the U.S. Securities
Act), or the securities laws of any state or other
jurisdiction of the United States, and may not be offered
or sold in the United States or to any person acting for the
account or benefit of a person in the United States except
in accordance with an available exemption from, or in a
transaction not subject to, the registration requirements
of the U.S. Securities Act and any other applicable
securities laws.
Australia
This document and the offer of New Shares under the
Offer are being made in Australia in reliance on the
Australian Securities and Investments Commission
Corporations (Foreign Rights Issues) Instrument 2015/356
or otherwise to persons to whom the Offer can be made
without a formal disclosure document under Chapter 6D
of the Corporations Act 2001 (Cth) (the “Corporations
Act”).
This document (whether alone or together with the
Investor Presentation) is not a prospectus, product
disclosure statement or any other formal disclosure
document for the purposes of Australian law or the
Corporations Act and is not required to, and does not,
contain all the information which would be required in a
disclosure document under Australian law or the
Corporations Act. It contains references to dollar
amounts which are not Australian dollars, may contain
financial information which is not prepared in accordance
with Australian law or practices, may not address risks
associated with investment in foreign currency
denominated investments and does not address
Australian tax issues.
Rua is a company which is incorporated in New Zealand
and the relationship between it and investors will be
largely governed by New Zealand law. This document has
not been, and will not be, lodged or registered with the
Australian Securities and Investments Commission or the
Australian Securities Exchange and Rua is not subject to
the continuous disclosure requirements that apply in
Australia.
Eligible Shareholders and other investors should not
construe anything in this document as legal, business or
tax advice nor as financial product advice for the
purposes of Chapter 7 of the Corporations Act.
Pursuant to the ASIC Corporations (Foreign Rights Issues)
Instrument 2015/356, Australian residents may also be
limited in the number of Additional New Shares they may
be allocated pursuant to the Oversubscription Facility if
and to the extent such allocation would result in more
than 10% of the maximum number of New Shares being
offered to Australian residents.
No guarantee
There is no guarantee that the Offer will proceed nor any
guarantees about the future performance of Rua or any
return on any investment made under this document.
Decision to participate in the Offer
The information in this document does not constitute
financial product advice or a recommendation to acquire
New Shares. This document has been prepared without
taking into account the investment objectives, financial,
or taxation situation or particular needs of any Eligible
Shareholder or other investor.
Before deciding whether to invest in New Shares,
you must make your own assessment of the risks
associated with an investment in Rua
(including the inherent uncertainties as to solvency and
the summary of key risks in Appendix B of the Investor
Presentation (“Key Risks”)), and consider whether such
an investment is suitable for you having regard to publicly
available information (including the Investor Presentation
and Rua’s other market releases lodged with the NZX),
your personal circumstances and following consultation
with a financial or other professional adviser. Please read
this document carefully and in full before making that
decision.
Forward looking statements
This document contains certain statements that relate to
the future. Such forward looking statements are not a
guarantee of future performance and involve known and
unknown risks, uncertainties, assumptions and other
factors, many of which are beyond the control of Rua, and
which may cause the actual results, performance or
achievements of Rua to differ materially from those
expressed or implied by such statements.
Under no circumstances should you regard the inclusion
of forward looking statements in this document as a
guarantee of future performance.
The statements, although made in good faith, involve
known and unknown risks, uncertainties and
assumptions, many of which are beyond Rua’s control.
Privacy
Any personal information provided by Eligible
Shareholders online will be held by Rua and/or
Computershare at the addresses set out in the Directory
at the back of this document. This information will be
used for the purposes of administering your investment in
Rua and will be disclosed to third parties only with your
consent or if required by law. Under the Privacy Act 2020
(New Zealand), you have the right to request access to,
and correction of, personal information held about you.
Dividend policy
The payment of dividends is at the discretion of the Board.
The Board has no present intention to make a distribution
for the foreseeable future. This policy may change from
time to time at the discretion of the Board in the future.
Enquiries
Enquiries about the Offer can be directed to an NZX Firm
or your financial or legal adviser. If you have any questions
about your Entitlement, or how to apply online, please
contact Computershare.
Times
All references to time in this document are to New
Zealand time.
Defined terms
Capitalised terms used in this document have the
specific meaning given to them in the Glossary at the
back of this document or in the relevant section of this
document.
Letter from the Chair
Dear Shareholders,
On behalf of the directors of Rua, we are pleased to offer Eligible Shareholders the opportunity to participate in our
renounceable rights issue of 1 New Share for every 3 Existing Shares held on the Record Date at an issue price of
$0.025 per New Share.
On Tuesday, 22 September, Rua released its 2026 Annual Report, which includes Rua’s audited consolidated financial
results for the 12-month period to 30 June 2026 (the “2026 Annual Report”).
A copy of the 2026 Annual Report, shareholder update and other announcements made by the company are available
at https://www.nzx.com/companies/RUA/announcements
FY26 marked an important period of meaningful commercial progress for Rua. Our export-led strategy is delivering
tangible results, with revenue increasing to $2.9 million, compared with $1.9 million in FY25, alongside continued
expansion across our key international markets. We have strengthened our position in established markets and opened
important new growth pathways, demonstrating the increasing international demand for high-quality New Zealand-
grown medicinal cannabis.
Most significantly, during the year Rua secured its largest export agreement to date, signing a major UK sales and
distribution agreement with one of the world’s leading medical cannabis companies, expected to generate NZ$10
million in revenue over its initial two-year term.
This new export agreement represents more than a future opportunity. It is an important commercial validation of the
strategy Rua has been pursuing: building an export-led business founded on differentiated New Zealand genetics, high-
quality cultivation and access to established international markets.
The next phase for Rua is to convert this commercial momentum into sustained revenue growth. Doing so requires
investment in inventory and working capital to meet increasing customer demand. The capital sought through this Offer
will therefore primarily support the fulfilment of customer demand and the conversion of available market
opportunities into revenue, enabling Rua to maximise the value of the opportunities now available to it.
Based on Rua’s current sales expectations for FY27, assuming sufficient funding is in place, and the expected costs of
delivering our global growth strategy, the target proceeds from the Offer - together with the anticipated proceeds from
the potential sale of the Gisborne manufacturing facility - are expected to provide the funding required to progress Rua
towards a self-sustaining position.
If sufficient funds are not raised under the Offer, or if the Gisborne manufacturing facility sale is further delayed, Rua
may need to reconsider its current strategy. This could constrain anticipated growth and/or require us to explore
alternative capital-raising options. It may also affect our ability to continue as a going concern. Under the Offer, Eligible
Shareholders who subscribe for their Entitlement in full may also apply for any number of Additional New Shares at the
same Issue Price under the Oversubscription Facility. Eligible Shareholders have until 5:00pm on 15 October 2026 to
apply under the Offer at the following link: www.shareoffer.co.nz/rua.
If you are a Custodian or hold your Shares in Rua through a Custodian (for example, Sharesies), please refer to
paragraphs 13 and 14 of the Terms and conditions section of this document.
Shareholders who choose not to take up their Entitlements may sell some or all of their Rights on the NZX Main Board
by instructing your broker or an NZX Firm. Rights trading will be available on NZX from 28 September until 9 October
2026. However, due to anticipated low liquidity and the likely low value of the Rights, it is highly uncertain whether there
will be sufficient liquidity to support any meaningful Rights trading. Shareholders who choose not to take up their
Entitlements will have their percentage shareholding diluted. The directors of Rua may also place any shortfall in the
Offer with new investors at the same price as the Issue Price and within 3 months of the close of the Offer in
accordance with the NZX Listing Rules.
This document should be read together with the Investor Presentation and other important information which is
available to Eligible Shareholders at www.shareoffer.co.nz/rua. These documents contain important information about
Rua and the risks associated with an investment in Rua. Before making your investment decision, I encourage you to
read these documents in full, and importantly, seek independent financial advice where further support is required.
Ngā Mihi,
Anna Stove
Chair
Key Terms of the Offer
The Offer
A pro-rata renounceable rights issue of 1 New Share for every 3 Existing Shares held on
the Record Date, with fractional Entitlements being rounded down to the nearest
share.
Eligible Shareholders Shareholders with registered addresses in the Offer Jurisdictions on the Record Date.
Issue Price $0.025 per New Share.
Offer Size Up to $2,828,681.
Rights
Eligible Shareholders may take up all or some or none of their Rights. Rights will be
quoted on the NZX Main Board so Eligible Shareholders may sell all or some of their
Rights on the NZX Main Board between 28 September 2026 and 9 October 2026.
Eligible Shareholders do not pay for the Rights themselves. Eligible Shareholders will
pay only for the New Shares issued to them if they choose to take up all or some of
their Rights.
Exercising Rights
purchased on the NZX
Rights purchased on the NZX may only be exercised by purchasers that meet eligibility
requirements. In particular, rights may not be exercised by purchasers that are in the
United States or who are acting for the account or benefit of persons in the United
States (to the extent such persons are acting for the account or benefit of persons in
the United States). Potential purchasers of Rights should familiarise themselves with
the requirements for exercise, which are set out in this document.
Oversubscriptions
If you accept your Entitlement in full, you may apply for any number of Additional New
Shares pursuant to the Oversubscription Facility.
Any Additional New Shares applied for under the Oversubscription Facility will be
issued at the issue price of $0.025.
Australian residents may however be limited in the number of Additional New Shares
they may be allocated pursuant to the Oversubscription Facility if and to the extent
such allocation would result in more than 10% of the maximum number of New Shares
being offered to Australian residents.
Maximum number of
New Shares being
offered
113,147,235 New Shares.
When to apply
Applications must be received by 5:00pm on the Closing Date (being Thursday, 15
October 2026, unless extended).
How to apply
Applications may be made online at www.shareoffer.co.nz/rua.
To complete an online application, you will be required to enter your CSN/Holder
number. Payment for applications must be made online by direct credit prior to the
Closing Date (5:00pm on Thursday, 15 October 2026, unless extended).
If you are a Custodian, please see paragraphs 13 and 14 in the Terms and conditions
section of this document.
If you hold your Shares through a Custodian, please provide your Custodian with your
instructions so that they may apply on your behalf in accordance with paragraphs 13
and 14 in the Terms and conditions section of this document.
No underwriting The Offer is not underwritten
While participation in the Offer is optional, if Eligible Shareholders choose not to take up their Entitlement, their
shareholdings in Rua will be diluted.
Important Dates
Announcement of the Offer Tuesday, 22 September 2026
Rights Trading Opens
(Rights trading commences on the NZX Main Board)
Monday, 28 September 2026
Record Date
(for determining eligibility to participate in the Offer and Entitlements)
5pm, Tuesday, 29 September 2026
Opening Date of the Offer
(including mailing/emailing of Offer documentation)
2pm, Wednesday, 30 September 2026
Rights Trading Closes
(Rights trading closes on the NZX Main Board at the close of trading)
Friday, 9 October 2026
Closing Date of the Offer
(being the date by which applications and payment must be received)
Thursday, 15 October, 2026
Announcement of Results of the Offer Tuesday, 20 October 2026
Issue Date
(for the allotment and issue of the New Shares)
Wednesday, 21 October 2026
Quotation of New Shares on NZX Main Board Wednesday, 21 October 2026
Holding Statements Dispatched Tuesday, 27 October 2026
These dates are subject to change and are indicative only. Rua reserves the right to amend this timetable (including by
extending the Closing Date) subject to applicable laws and the Listing Rules. Rua reserves the right to withdraw the
Offer and/or issue New Shares at any time before the Issue Date in its absolute discretion.
Actions to be taken by Eligible Shareholders
Available actions in respect of your Rights
If you are an Eligible Shareholder, you may take the following actions:
• take up all or some of your Rights; or
• take up all of your Rights and apply for Additional New Shares as a part of the Oversubscription Facility; or
• sell all or some of your Rights on the NZX Main Board; or
• take up some of your Rights, and sell all or some of the remaining balance on the NZX Main Board; or
• do nothing with all or some of your Rights.
Take up all or some of your rights
If you are an Eligible Shareholder and wish to take up all or some of your Rights, you can apply online at
www.shareoffer.co.nz/rua.
If you are a Custodian, please see paragraphs 13 and 14 in the Terms and Conditions section of this document.
If you hold your Shares through a Custodian, please provide your Custodian with your instructions so that they may
apply on your behalf in accordance with paragraphs 13 and 14 in the Terms and Conditions section of this document.
Apply for Additional New Shares as a part of the Oversubscription Facility
Eligible Shareholders who take up their Rights in full have the opportunity to apply for Additional New Shares as a part
of the Oversubscription Facility. To participate in the Oversubscription Facility you must:
a. take up your Rights in full as directed via the online application process; and
b. apply for New Shares under the Oversubscription Facility as directed via the online application process.
Sell your Rights
The Rights are renounceable. This enables Eligible Shareholders who do not wish to take up all or some of their
Entitlement to sell those Rights they have not taken up.
If you wish to sell all or some of your Rights, this can be effected on the NZX Main Board by instructing an NZX Firm to
sell all or some of your Rights. You will need to provide your Authorisation Code (FIN) and your Common Shareholder
Number (CSN) to the NZX Firm who you are instructing to sell your Rights. You may be required to pay brokerage in
respect of that sale. If you are not an NZX Shareholder and you wish to sell your Rights on the NZX Main Board, please
contact your broker or an NZX Firm.
Trading of Rights will commence on the NZX Main Board under the code “RUARC” on 28 September 2026 and will end at
the close of trading on 9 October 2026. Your Rights may be sold on the NZX Main Board between these dates.
Do Nothing
If you do nothing, your Rights will lapse. You will not be able to subscribe for any New Shares and your shareholding
percentage will be diluted by the issue of New Shares under the Offer.
Terms and Conditions
1. The Offer
The Offer is an offer of New Shares in Rua to Eligible
Shareholders under a pro-rata renounceable rights issue.
Under the Offer, Eligible Shareholders are entitled to
subscribe for 1 New Share for every 3 Existing Shares held
by them on the Record Date (with any fractional
Entitlements rounded down) and may also apply for
Additional New Shares pursuant to the Oversubscription
Facility.
The New Shares are of the same class as (and rank
equally with) Rua’s Existing Shares which are quoted on
the NZX Main Board. Rua will take any necessary steps to
ensure that the New Shares are, immediately after the
issue, quoted.
The Rights will be quoted on the NZX Main Board. Eligible
Shareholders may take up all or some or none of their
Rights. Eligible Shareholders may also sell all or some of
their Rights on the NZX Main Board between 28
September 2026 and 9 October 2026.
2. Issue Price
The Issue Price is $0.025 per New Share. The Issue Price
must be paid in full by 5:00pm on the Closing Date (being
15 October 2026, unless extended). Rua may accept late
applications and payment of application monies in its
sole discretion, but has no obligation to do so.
Rua may also accept or reject (at its discretion) any online
application which it considers is not completed correctly,
and/or may correct any errors or omissions on any online
application.
If an Eligible Shareholder fails to take up its Entitlement by
applying for any New Shares and paying the application
monies for those New Shares by the Closing Date
(5:00pm on 15 October 2026, unless extended), that
Eligible Shareholder’s Rights will lapse.
As required by the Listing Rules, if Rua receives, before
the Closing Date, a renunciation and an acceptance in
respect of the same Right(s), the renunciation shall be
given priority to the acceptance.
All application monies received will be held in a trust
account with Computershare until the corresponding
New Shares are allotted or the application monies are
refunded. Interest earned on the application monies will
be for the benefit, and remain the property, of Rua and will
be retained by Rua whether or not the issue of New
Shares takes place. Any refunds of application monies
will be made within 5 Business Days of the issue of New
Shares (or such earlier date that the decision not to
proceed with the Offer is made).
3. Eligibility
The Offer is only open to Eligible Shareholders, being
those persons with registered addresses in the Offer
Jurisdictions (or as Rua may otherwise determine in
compliance with applicable laws), who are registered as
Shareholders at the Record Date.
The Rights of any shareholder that is not an Eligible
Shareholder will be transferred to a nominee who will
endeavour to sell those Rights on the NZX Main Board.
Any proceeds (less transaction costs) will be paid to
those shareholders that are not Eligible Shareholders on a
pro rata basis.
4. Oversubscription Facility
Eligible Shareholders who accept their full Entitlement
may also apply for Additional New Shares (in excess of
their Entitlement) at the Issue Price pursuant to the
Oversubscription Facility.
Eligible Shareholders may apply for any number of
Additional New Shares, but there is no guarantee that
they will be allocated any or all of the Additional New
Shares for which they apply.
No applicant for Additional New Shares will be allocated
any greater number of Additional New Shares than the
number for which they have applied and paid.
Rua may scale applications under the Oversubscription
Facility in such manner as the directors of Rua consider
equitable and in the interests of the company.
In particular, for the purposes of the ASIC Corporations
(Foreign Rights Issues) Instrument 2015/356, Australian
residents cannot be allocated Additional New Shares
pursuant to the Oversubscription Facility to the extent
such allocation would result in more than 10% of the
maximum number of New Shares being offered to
Australian residents.
The Rua directors’ decision on scaling will be final.
If you are a Custodian, or hold your Shares through a
Custodian, please see paragraphs 13 and 14 below.
5. Opening and Closing Dates
The Offer will open for receipt of acceptances at 2:00pm
on 30 September 2026 (the “Opening Date”). The last day
for receipt of applications with payment is 5:00pm on 15
October 2026 (the “Closing Date”), subject to Rua
varying or extending those dates as permitted by and in
accordance with applicable laws and the Listing Rules.
6. Issue of New Shares
New Shares are expected to be allotted and issued on 21
October 2026 (the “Issue Date”).
In the event that the Closing Date for the Offer is
extended, Rua reserves the right to issue New Shares on
or about 21 October 2026, and weekly thereafter as any
further applications are received, until the date up to 5
Business Days after any extended Closing Date.
Statements for New Shares will be issued and mailed in
accordance with the Listing Rules.
7. Terms and ranking of New Shares
New Shares allotted and issued will be fully paid and will
be the same class as (and rank equally in all respects
with) the Existing Shares which are quoted on the NZX
Main Board on the Issue Date. They will give the holder the
right to one vote on a resolution at a meeting of
shareholders (subject to any restrictions in Rua’s
constitution or the Listing Rules), the rights to dividends
authorised by Rua’s board of directors and the right to a
proportionate share in any distribution of surplus assets
of Rua on any liquidation.
8. Partial acceptance
If you are an Eligible Shareholder, you are not required to
subscribe for all of the New Shares to which you would be
entitled under the Offer. You may subscribe for a
proportion of your New Shares or allow your entire
Entitlement to lapse.
9. Minimum amount raised
There is no minimum amount that must be raised for the
Offer to proceed.
10. NZX Main Board quotation
The New Shares will be quoted on the NZX Main Board
upon completion of allotment procedures. The NZX Main
Board is a licensed market operated by NZX, which is a
licensed market operator regulated under the FMCA.
NZX accepts no responsibility for any statement in this
document.
11. Rights Trading
Application has been made for permission to quote the
Rights on the NZX Main Board and all NZX requirements
have been duly complied with. However, NZX accepts no
responsibility for any statement in this document.
Eligible Shareholders may sell all or some of their Rights
on the NZX Main Board between 28 September 2026 and
9 October 2026. If you are not an NZX Shareholder and
you wish to trade your Rights on the NZX Main Board,
please contact your broker or an NZX Firm.
The right to apply for Additional New Shares under the
Oversubscription Facility is available to Eligible
Shareholders who take up their Rights in full only.
Investors who acquire Rights on the NZX Main Board and
are not Eligible Shareholders on the Record Date are not
entitled to apply for Additional New Shares under the
Oversubscription Facility.
Investors who acquire Rights on the NZX Main Board or
otherwise will, by acquiring those Rights, and applying to
take up all or part of those Rights, be deemed to agree to
make and be subject to the representations, declarations,
warranties and agreements on the website.
Investors should note that if they purchase Rights in a
transaction on the NZX Main Board or otherwise, in order
to take up or exercise those Rights and subscribe for New
Shares they:
• must be:
o located in/with a registered address in New
Zealand or Australia (including, for the
avoidance of doubt, Eligible Shareholders); or
o any other person to whom Rua consider an offer
of Rights or New Shares may be made without
the need for a lodged prospectus or other
formality (other than a formality with which Rua
is willing to comply); and
• must not be in the United States or acting for the
account or benefit of a person in the United States in
respect of the purchase or exercise of such Rights
and the subscription for New Shares. The Rights may
not be purchased, traded, taken up or exercised by
any person in the United States or by any person
acting for the account or benefit of a person in the
United States (to the extent such persons are acting
for the account or benefit of persons in the United
States).
If an investor does not satisfy the above conditions, they
will not be entitled to take up Rights or subscribe for New
Shares. It is the responsibility of purchasers of Rights to
inform themselves of the eligibility criteria to exercise the
Rights. If holders of Rights after the end of the Rights
trading period do not meet the eligibility criteria, they will
not be able to exercise the Rights. In the event that
holders are not able to take up their Rights, those Rights
will form part of the shortfall to be offered to new
investors, and holders may receive no value for them.
12. NZX Listing Rules
The issue of New Shares under the Offer is being
undertaken under NZX Listing Rule 4.3.1(a) (Pro-rata
issues) and 4.4 (Rules applicable to pro-rata issues).
In addition, the directors of Rua plan to place any shortfall
in the Offer with new investors, at the Issue Price, in
accordance with Listing Rule 4.4.
13. Custodians
In order to participate in the Offer on behalf of one or
more beneficial owners, Custodians must provide the
following information by email to Computershare and
make payment by way of electronic funds transfer:
a) the number of Participating Beneficiaries (as defined
in paragraph 14 below) and their names and
addresses;
b) in respect of each of the Participating Beneficiaries,
the number of Existing Shares that the Participating
Beneficiary holds and the number and dollar amount
of Rights, as well as the Additional New Shares the
Participating Beneficiary has instructed the
Custodian, either directly or indirectly through a
Downstream Custodian (as defined in paragraph 14
below), to apply for on behalf of that Participating
Beneficiary;
c) where the Custodian holds Existing Shares on behalf
of a Participating Beneficiary indirectly, through one
or more Downstream Custodians, the name and
address of each Downstream Custodian; and
d) an acknowledgement that the certifications
described in paragraph 14 below are deemed to have
been provided to Rua.
14. Custodian certifications
If a Custodian applies in the manner described above to
purchase New Shares on behalf of one or more beneficial
owners, the Custodian will be deemed to have certified to
Rua that:
a) the Custodian holds Existing Shares on behalf of:
i) one or more other persons that are not
Custodians (who would be Eligible
Shareholders if they held Existing Shares
directly); and/or
ii) another Custodian (Downstream Custodian)
that holds beneficial interests in Existing Shares
on behalf of one or more other persons to which
those interests relate, on the Record Date,
(each a Participating Beneficiary) who have
subsequently instructed the Custodian, and/or
the Downstream Custodian, to participate in
the Offer on their behalf;
b) the information set out in the email required to be
provided to Computershare under paragraph 13
above is true and accurate;
c) a copy of this document and the Investor
Presentation was given to each Participating
Beneficiary; and
d) the beneficial owner on whose behalf the Custodian
is submitting an application for New Shares is not
making an application as an Eligible Shareholder
under the Offer in respect of the Existing Shares held
by the Custodian on behalf of that beneficial owner,
and no other Custodian is submitting an application
for New Shares under the Offer for that beneficial
owner in respect of those Existing Shares.
Rua is not required to determine whether or not any
Eligible Shareholder is acting as a Custodian, or the
identity or residence of any beneficial owners of Shares.
Where any holder is acting as a Custodian for a foreign
person, that holder, in dealing with its beneficiary, will
need to assess whether indirect participation by the
beneficiary in the Offer is compatible with applicable
foreign laws. Eligible Shareholders who are Custodians
are therefore advised to seek independent advice as to
how to proceed.
For the avoidance of doubt, each Custodian is
responsible for determining whether an underlying
beneficial holder of Existing Shares for whom that
Custodian acts as Custodian is an Eligible Shareholder.
If you hold your Shares through a Custodian, please
provide your Custodian with your instructions so that your
Custodian may apply on your behalf in accordance with
the information above.
15. Amendments to the Offer and waiver of
compliance
Notwithstanding any other term or condition of the Offer,
Rua may, at its discretion and to the maximum extent
permitted by law:
a) make non-material modifications to the Offer on
such terms and conditions as it thinks fit (in which
event applications for New Shares under the Offer
will remain binding on the applicant notwithstanding
such modification and irrespective of whether an
application was received by the Computershare
before or after such modification is made); and/or
b) suspend or terminate the Offer at any time prior to
the issue of the New Shares under the Offer
(including by reviewing the timetable for the Offer).
If the Offer is terminated, application monies will be
refunded to applicants without interest within 5 Business
Days of termination.
Rua reserves the right to waive compliance by any
applicant under the Offer with any provision of these
terms and conditions.
Rua will notify NZX of any waiver, amendment, variation,
suspension, withdrawal or termination of the Offer.
16. Governing law
These terms and conditions shall be governed by and
construed in accordance with the laws of New Zealand.
17. Other disclosures
Investors are encouraged to review the Rua audited
financial statements for the 12-month period ended 30
June 2026. The audited financial statements are included
in the 2026 Annual Report (at
www.nzx.com/companies/RUA/announcements)
Investors should also consider the factors discussed in
Rua’s Investor Presentation dated 22 September 2026
which includes details of the rationale and risks relating
to the Offer.
Other announcements about Rua, including any
announcement made after the date of this document, are
available and can be accessed at www.nzx.com under
the ticker code “RUA”.
Glossary
2026 Annual Report means Rua’s annual report for the year ended 30 June 2026.
Additional New Shares means New Shares which an Eligible Shareholder applies for over and above their Entitlement
under the Oversubscription Facility.
Business Day has the meaning given to that term in the Listing Rules.
Computershare means Computershare Investor Services Limited.
Closing Date means 5:00pm on 15 October 2026 (unless extended beforehand by notice in writing to NZX).
Custodian means any Eligible Shareholder that:
a. is a trustee corporation or a nominee company and holds Existing Shares on the Record Date by reason only of
acting for another person in the ordinary course of business of that trustee corporation or nominee company; or
b. holds Existing Shares by reason only of being a bare trustee of a trust to which the Existing Shares are subject.
Eligible Shareholders means a Shareholder with a registered address in the Offer Jurisdictions, as at the Record Date.
Entitlement means the number of Rights to which an Eligible Shareholder is entitled.
Existing Shares means a Share in Rua on issue on the Record Date.
FMCA means the Financial Markets Conduct Act 2013.
Rua means Rua Bioscience Limited (New Zealand company no. 6484092 with NZX ticker code: RUA).
Investor Presentation means the investor presentation relating to the Offer which was released by Rua on 22
September 2026.
Ineligible Shareholder A Shareholder other than an Eligible Shareholder.
Issue Date means 21 October 2026.
Issue Price means $0.025 per New Share.
Listing Rules means the NZX listing rules, as amended from time to time and for so long as Rua is listed by NZX.
New Shares means an ordinary share in Rua, being of the same class as, and ranking equally in all respects with, the
Existing Shares at the time of issue of the New Shares.
NZX means NZX Limited.
NZX Firm means any entity designated as an NZX Firm under the Participant Rules of NZX.
NZX Main Board means the main board equity security market operated by NZX.
Offer means the offer to subscribe for New Shares made to Eligible Shareholders pursuant to this document.
Offer Jurisdictions means New Zealand, Australia or such other places where a shareholder satisfies Rua that the
Offer can lawfully be made and accepted. However, Shareholders in the United States are not eligible to participate in
the Offer. Similarly, Shareholders (including trustees, Custodians and nominees) who hold Shares on behalf of persons
in the United States, or are acting for the account or benefit of persons in the United States, are not eligible to
participate in the Offer on behalf of those persons.
Opening Date means 30 September 2026.
Oversubscription Facility means the facility that entitles an Eligible Shareholder who accepts their Entitlement in full
to also apply for Additional New Shares.
Record Date means 5pm 29 September 2026.
Renounceable means an Eligible Shareholder can sell or otherwise transfer its Rights (which are quoted) to a third
party (whether or not an existing Shareholder) who can use those Rights to buy the New Shares that the Eligible
Shareholder is otherwise entitled to.
Rights means the renounceable right to subscribe for one New Share at the Issue Price, issued pursuant to the Offer.
Share means one ordinary fully paid share in Rua.
Shareholder means a registered holder of Shares.
Takeovers Code means the takeovers code set out in the schedule to the Takeovers Regulations 2000.
All references to time are to New Zealand time, references to currency are to New Zealand dollars, and any references
to legislation are references to New Zealand legislation unless stated or defined otherwise.
Directory
Issuer
Rua Bioscience Limited
PO Box 1387
Gisborne 4040
Aotearoa New Zealand
Legal Adviser
Lowndes Jordan
Level 15, HSBC Tower
188 Quay Street, Auckland CBD
Auckland 1010
Registrar
Computershare Investor Services Limited
Level 2, 159 Hurstmere Road
Ta k a p u n a
Auckland 0622
New Zealand
Telephone: +64 9 488 8793
Freephone: 0800 650 034
Website: www.shareoffer.co.nz/rua
Email: rua@computershare.co.nz
---
Investor Presentation
22 September 2026
This presentation contains summary information about Rua Bioscience Limited (Rua) and its activities that is current as at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Rua or that would be required in a
product disclosure statement for the purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or a prospectus orother disclosure document for the purposes of the laws of any other jurisdiction. Rua is subject to a disclosure obligation
that requires it to notify certain material information to NZX Limited (NZX) for the purpose of that information being made available to participants in the market and that information can be found by visiting www.nzx.com/companies/rua
. This
presentation should be read in conjunction with Rua's other periodic and continuous disclosure announcements released to NZX.
Proposed Offer
This presentation has been prepared by Rua in relation to a proposed offer of new ordinary shares in Rua (Shares) by way of a renounceable entitlement offer (Offer). Notwithstanding the proposed Offer, this presentation is for information purposes only
and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Rua reserves the right not to proceed with the Offer, to vary the dates of the Offer or to withdraw the Offer without prior notice.No information set out in
this presentation will form the basis of any contract.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial product advice or investment advice or a recommendation to acquire Rua securities, and has been prepared without taking into account the objectives, financial situation or needs of
investors. Before making an investment decision, prospective investors should consider the appropriateness of the informationhaving regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or
other professional advisor if necessary.
Forward-looking statements
This presentation may contain forward-looking statements that reflect Rua’s current views with respect to future events. This includes statements regarding the timetable, conduct and outcome of the Offer and the use of proceeds thereof, statements
about the plans, objectives and strategies of the management of Rua, statements about the industry and the markets in which Rua operates, and statements about the future performance of, and outlook for, Rua’s business. Any indications of, or guidance
or outlook on, future earnings or financial position or performance are also forward-looking statements. All such forward-looking statements, by their very nature, involve inherent known and unknown risks, significant uncertainties, assumptions,
contingencies, and other factors, many of which are outside the control of Rua, are difficult to predict, and which could causeactual results or performance of Rua to materially differ from any future results or performance expressed or implied by such
forward looking statements. Variations could either be materially positive or materially negative. The information is stated only as at the date of this presentation. Except as required by law or regulation (including the NZX Listing Rules), Rua undertakes
no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To the maximum extent permitted by law, the directors of Rua, Rua and any of its related bodies corporate and affiliates,
and their respective officers, partners, employees, agents, associates and advisers do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of such information, or the likelihood of fulfilment of any
forward-looking statement or any event or results expressed or implied in any forward-looking statement, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).
Any estimates or projections as to events that may occur in the future (including any projections of revenue, capacity, earningsand performance) are based upon the best judgement of Rua from the information available as of the date of this presentation.
A number of factors could cause actual results or performance to vary materially from the projections, including the risk factors set out in this presentation. Investors should consider the forward-looking statements in this presentation in light of those risks
and disclosures.
Investors are strongly cautioned not to place undue reliance on any forward-looking statements.
Financial data
All dollar values are in New Zealand dollars unless otherwise stated.
This presentation should be read in conjunction with, and subject to, the explanations and views of future outlook on market conditions, earnings and activities given in the announcements relating to the audited financial results for the year ended 30
June 2026.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject tothe effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.
Disclaimer and important notice 1 of 2
Pastperformance
Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of(a nd provides no guidance as to) future Rua performance, including future financial position or share price performance. Past performance
information provided in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) a promise, representation, warranty or guarantee as to the past, present or future performance of Rua.
Investment risk
An investment in securities of Rua is subject to investment risk and other known and unknown risks, some of which are beyond thecontrol of Rua. Rua does not guarantee any particular return or the performance of Rua shares.
Not an offer
This presentation is not a prospectus or product disclosure statement or other offering document under New Zealand or Australianlaw or any other law (and will not be filed with or approved by any regulatory authority in New Zealand, Australia or any other
jurisdiction). This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Any decision to purchase Shares in the Offer must be made on the basis of all information provided in
relation to the Offer, including information to be contained or referred to in a separate offer document made available on NZX (Offer Document) and Rua’s other periodic and continuous disclosure announcements released to NZX. Any eligible shareholder who wishes
to participate in the Offer should consider the Offer Document, in addition to Rua’s other periodic and continuous disclosureannouncements released to NZX, in deciding to apply under the Offer. Anyone who wishes to apply for Shares under the Offer willneed to
apply in accordance with the instructions contained in the Offer Document and the application form. The distribution of this presentation outside New Zealand or Australia may be restricted by law. Any recipient of this presentation who is outside New Zealand or
Australia must seek advice on and observe any such restrictions.
Distribution of presentation
This presentation may not be reproduced in any form or further distributed to any other person, passed on, directly or indirectly, to other person, or published, in whole or in part, for any purpose. Additionally, this presentation must not be distributed in any
jurisdiction outside New Zealand and Australia in circumstances in which the distribution of this presentation would be unlawful. The distribution of this presentation in jurisdictions outside New Zealand and Australia may be restricted by law, and personsinto whose
possession this presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of Rua, any person named in this presentation or any of their affiliates accept or shall haveany liability to
any person in relation to the distribution or possession of this presentation from or in any jurisdiction.
No offer in the United States
This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Any shares described in this presentation have not been, and will not
be, registered under the US Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of theUnited States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the
US Securities Act of 1933, as amended, and applicable US state securities laws.
Disclaimer
None of Rua or Rua's advisers (including the lead manager for any offer of Rua securities) or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorised, permitted or caused the issue,submission,
dispatch or provision of this presentation and, except to the extent referred to in this presentation, none of them makes or purports to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of
them.
To the maximum extent permitted by law, none of Rua and its advisers (including the lead manager for any offer of Rua securities), affiliates, related bodies corporate, nor their respective directors, officers, partners, employees and agents (Specified Persons) makes any
representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in thispresentation and none of them shall have any liability (including in tort or for negligence) for:
-any errors or omissions in this presentation; or
-any failure to correct or update this presentation, or any other written or oral communications provided in relation to this presentation; or
-any claim, loss or damage (whether foreseeable or not) arising from the use of any information in, or omitted from, this presentation or otherwise arising in connection with this presentation or the information contained in, or omitted from, it.
To the maximum extent permitted by law, you agree that you will not bring any proceedings against or hold or purport to hold anySpecified Person liable in any respect for this presentation or the information in this presentation and waive any rights youmay otherwise
have in this respect.
Acceptance
By reading this presentation, you agree to be bound by the foregoing limitations and restrictions and. in particular, will bedeemed to have represented, warranted, undertaken and agreed that: (i) you have read and agree to comply with the contents of this Disclaimer
and Important Notice; (ii) you are permitted under applicable laws and regulations to receive the information contained in this presentation; (iii) you will base any investment decision solely on information released by Rua via NZX (including the Offer Document); and
(iv) you agree that this presentation may not be reproduced in any form or further distributed to any other person, passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.
Disclaimer and important notice 2 of 2
Kia ora, and thank you
A note from the Chair and Chief Executive
•Last year we asked for your support to take Rua through a pivotal stage of growth. You supported us, and that
support has helped us build the platform we have today.
•Much has changed over the past 12 months. Revenue has grown, our capital-light model is demonstrating
improved operating leverage, and Rua is now selling into five medicinal cannabis markets.
•Most importantly, customers are demonstrating their confidence in Rua's products and capabilities. Our largest
export agreement to date with a clinic chain in the United Kingdom is a significant example of that progress.
•The strategy is producing commercial evidence, but we need further capital to fulfil and scale the opportunities
before us. Rua is seeking to raise up to $2.8m through a pro-rata rights offer.
•The capital will fund this growth through mainly inventory for international markets, in particular the UK.
•The company continues to explore all options for the sale of the Gisborne manufacturing facility in order to free up
capital, and also to reduce operating expenditure further.
•Rua has secured a further $0.3m of existing convertible notes will convert to equity at the offer price if the offer
raises a minimum of $1.5m.
Same kaupapa, stronger evidence
We remain focused on our strategy
•A capital-light model anchored in genetics and distribution, not cultivation or manufacturing infrastructure.
•Outsourcing commercial manufacturing has helped cut operating expenditure as revenue increases.
•New distribution and offtake agreements extend our reach without adding capital cost.
•The model is working: we are converting our genetics, partnerships and market access into growing international
sales
5
Revenue NZ$m
71%
Customer Revenue
Growth Year-on Year
International
markets
0.3
1.9
2.9
FY24FY25FY26
01
Our Strategy
Genetics and mātauranga at the core
Our community links is our point of difference
•Our edge starts with genetics selected in Te Tairāwhiti- cannabinoid and terpene profiles unique to Rua.
•We work with legacy growers, and we're proud of those connections - access to varieties available nowhere else.
•Genetics travel efficiently. Clones, licences and seed can move around the world with significantly less cost and
complexity than finished product - this is what makes our capital-light model possible.
•Our knowledge of controlled drugs allows us to work with psilocybin with the Tu Wairua collaboration to treat
methamphetamine addiction.
8
Germany | Australia
New Zealand | United
KingdomCzechia
Rua is doing medicinal cannabis differently in the NZ market
Unique Genetics
Rua’s point of difference
Rua has outsourced production to best-in-class global cultivation and manufacturing
partners. This provides access to significantly higher capacity which is close to
market and at a lower per unit cost, while avoiding the high capital costs of GMP
manufacturing.
Rua operates in a targeted segment of the market with the lowest capital requirements. This
means we can leverage our expertise to deliver scalable value with trusted partners.
From genetics to global markets
How genetics become revenue
•Clones exported live -Canada
•Licensed and grown out - Aotearoa, Canada
•Finished product via distribution partners –Germany, United
Kingdom, Australia
•Agreements established - Portugal
Six markets, one platform
•Aotearoa, New Zealand -our home market
•Australia - second-largest medicinal cannabis market
globally
•Germany - world's largest medicinal cannabis market
•United Kingdom -fastest-growing market
•Czechia - a new foothold, early growth
•Canada - a new genetic pool, first live clone exports
02
Investment Highlights
Evidence across six markets
The strategy is translating into commercial activity across established and new markets.
AUSTRALIA
Revenue almost doubled
Strong clinic relationships continue to
support our position in one of the world’s
most competitive markets.
UNITED KINGDOM
~NZ$10m expected (over 2yrs)
Largest export agreement to date; a
major customer commitment that
provides clear evidence of demand.
AOTEAROA NZ
Share and revenue up
New medical device launched and five
further product approvals received.
GERMANY
Delivered cost ↓ ~50%
Supplier renegotiation has materially
improved economics following a
regulatory reviewperiod and a year of
tough trading environment.
CZECHIA
First revenues booked
An early foothold in a market with room
to grow.
CANADA
First live clone export
Demonstrates how Rua’s genetics
platform can open further markets
without owned infrastructure.
The important point: progress is not dependent on a single market or contract.
Rua today: the strategy is producing commercial evidence
The business has moved from building the platform to demonstrating that the platform works, on a fixed cost base.
$2.9m
FY26 revenue
up 54% year-on-year
+71%
Customer revenue
growth
FY25 to FY26
3% ↓
Opex
Year-on-Year
5
International cannabis
markets
established commercial
pipelines
~NZ$10m
UK agreement
anticipated revenue over two
years
GENETICS
Te Tairāwhiti
PARTNERS
Capital-light
DISTRIBUTION
6 markets
CUSTOMERS
Demand
REVENUE
$2.9m
This is a commercial business with increasing demand. The largest constraint is working capital, not infrastructure.
Largest export supply agreement to date
Commercial validation of our strategy
~$NZ10m
anticipated revenue
over an initial two-year period
assuming Rua can fund the necessary
working capital
MAJOR UK CLINICAL CUSTOMER
Promoting and selling Rua products into
the UK market
Why this matters
New Zealand-grown
product
→
NZ growers + partners
→
UK distribution
The commercial model is already in place
SUPPLY
NZ growers in place
SCALE
Additional growers required
DEMAND
Customer commitment secured
The UK agreement is evidence that the strategy is working and not an
aspiration for the future.
The opportunity now is to supply anticipated demand.
Three research programmes, all rooted in Te Tairāwhiti
Rua is already working with partners on the next generation of botanical products.
19
Wairuakohu Project
Radula liverwort
A liverwort native to Aotearoa that produces
compounds understood to act on the same
receptors as cannabinoids. Rua is partnering with
researchers on its potential.
WairuakohuCharitable Trust, NZ Institute for Bioeconomy
Science, IO Limited
Tū Wairua Project
Psilocybin-containing mushrooms
Rua is contributing specialist cultivation and
regulatory capability to the TūWairua research
collaboration, led by the Rangiwaho Marae
community.
RangiwahoMarae, ESR, Uni of Auckland, Uni of Waikato,
Matai Medical Research, NZ Institute for Bioeconomy
Science
Cytisine from kōwhai
A native source of an established medicine
Cytisine, an alkaloid found in kōwhai, is a long-
established smoking-cessation medicine with a
substantial clinical evidence base, including New
Zealand-led trials.
IO Limited,
To be clear: no revenue from these programmes is assumed in FY27 or FY28. They integrate with our existing business, with Rua contributingcapability, licensing and
access rather than capital.
The capability we built for cannabis is not limited to cannabis
Longer-term research using our core knowledge and experience.
18
Now
FY26 – FY28
Medicinal cannabis
Five markets, established distribution, unique genetics. This is the business, and it is where
every dollar of this offer goes.
~100% of revenue
Research
FY28 onward
Cytisine, Wairuakohu, and TūWairua psilocybin
Three research collaborations that draw on the same licensing, regulatory and supply
capability Rua already runs every day.
Nil assumed
Exploratory
FY27 onwards
Further natural ingredients from Te Tairāwhiti
Early scoping of other botanical and rongoā ingredients from our rohe, guided by
kaitiakitanga and benefit-sharing.
Nil assumed
Contribution to FY27 revenue
Integration with Rua: Controlled-drug licensing, regulatory expertise, GMP supply relationships, high-hygiene cultivation, export permitting, mātaurangaMāori
and community relationships. Rua provides a framework of knowledge to integrate with new products in the future.
16
Growing without losing our kaupapa
Through Rua‘s scholarship programme, assisting Te
Tairawhiti students through their studies, they have
positively impacted
67
Students since 2020
Student Scholarship ProgrammeCompassionate Access Programme
Leveraging support from partners and local
community, Rua are now supporting up to 52
patients each month by supplying medicinal
cannabis through their Compassionate Access
Programme.
86
Patients supported
since April 2022
03
Why We're Raising
We need further capital to grow our revenue
•Growth at this pace needs working capital -inventory has to be funded ahead of sales as we scale into
established international markets.
•We have funded that working capital requirement since our last raise through a disciplined mix of equity and debt.
To sustain the current growth trajectory and convert demand into revenue, further shareholder support is required.
•We have also taken action to reduce our cost base and unlock capital from the property portfolio. We have
consolidated operations into the Gisborne manufacturing facility, reducing operating costs while establishing the
property as a tenanted, income-generating asset. We continue to pursue options to realisevalue from the
property and redeploy capital into the business.
•The offer is about funding growth, not building infrastructure. It provides the working capital required to fulfil
existing contracted demand and convert an increasingly visible sales pipeline into revenue.
•This is the same capital-light model that underpins our strategy. We are not seeking significant infrastructure
investment to enter new markets; we are funding the working capital required to supply products into markets
where demand, distribution and commercial pathways are already established.
Capital converts demand into revenue
The capital raised will be used primarily to fund inventory and working capital ahead of confirmed and
anticipated sales growth.
Particularly to fulfil the UK agreement, meet growing demand in Australia and Aotearoa, New Zealand, and support market entry in
Canada and Czechia.
DEMAND
UK agreement + growing
demand
in Australia & Aotearoa, NZ
WORKING CAPITAL
Fund inventory
ahead of sales
FULFILMENT
Deliver customer orders
and support market entry
MARGIN GROWTH
Convert established demand
into realised revenue
The majority of capital will be used for growth.
04
The Offer
Offer Details
21
Offer Size and
Structure
•1 for 3 pro-rata renounceable entitlement offer to raise up to ~$2.8 million (if fully subscribed)
•Up to approximately 113.1m new Rua shares to be issued (33% of existing shares on issue)
•Offer structure similar to 2025 rights offer with shortfall shares available to new investors
Offer Terms
•$0.025 per new share, representing a discount of 32% to the 20-day volume weighted average price of
Rua shares traded on the NZX Main Board up to 17 September 2026
•The offer is renounceable meaning shareholders who choose not to take up their entitlements may sell
some or all of their rights on the NZX Main Board (subject to sufficient demand for the rights)
•Shareholders who subscribe for their entitlements in full may also subscribe for any number of additional
shares through the oversubscription facility
•Further terms of the rights offer can be found in the offer document dated 22 September 2026 and at the
offer website: www.shareoffer.co.nz/rua
Use of Proceeds
•All net proceeds from the offer will be used to fund Rua’s working capital requirements and ongoing
operating expenses
Ranking •New shares issued under the Offer will rank equally in all respects with Rua’s existing ordinary shares
Offer Timetable
22
Announcement of the OfferTuesday, 22 September 2026
Rights Trading Opens
(Rights trading commences on the NZX Main Board)
Monday, 28 September 2026
Record Date
(for determining eligibility to participate in the offer and entitlements)
5pm, Tuesday, 29 September 2026
Opening Date of the Offer
(including mailing/emailing of Offer documentation)
2pm, Wednesday, 30 September 2026
Rights Trading Closes
(Rights trading closes on the NZX Main Board at the close of trading)
Friday, 9 October 2026
Closing Date of the Offer
(being the date by which applications and payment must be received)
Thursday, 15 October 2026
Announcement of Results of the OfferTuesday, 20 October 2026
Issue Date
(for the allotment and issue of the new shares)
Wednesday, 21 October 2026
Quotation of New Shares on NZX Main BoardWednesday, 21 October 2026
Holding Statements DispatchedTuesday, 27 October 2026
---
Corporate Action Notice
Page 1 of 3
Section 1: Issuer information
Name of issuer Rua Bioscience Limited
Class of Financial Product Ordinary shares
NZX ticker code RUA
ISIN NZRUAE0004S1
Name of Registry Computershare Investor Services Limited
Type of corporate action
(Please mark with an X in the relevant
box/es)
Share Purchase
Plan/retail offer
Renounceable
Rights issue or
Accelerated
Offer
x
Capital
reconstruction
Non-
Renounceable
Rights issue or
Accelerated
Offer
Call Bonus issue
Placement
Record date Tuesday, 29/09/2026
Ex Date (one business day before the
Record Date)
Monday, 28/09/2026
Currency NZD
External approvals required before
offer can proceed on an unconditional
basis?
N
Details of approvals required N/A
Section 2: Rights Issue or Accelerated Offer
2a: Rights Issue (i.e. non-accelerated)
Maximum number of Equity Securities
to be issued if offer is fully subscribed
Approximately 113,147,235 (subject to rounding)
ISIN of Rights (if applicable) NZRUAE0007S4
Oversubscription facility Y. New shares not taken up by eligible shareholders in the
rights issue will be offered through an oversubscription
facility. Eligible shareholders who take up their rights in full
have the opportunity to apply for additional new shares in
the oversubscription facility.
Details of scaling arrangements for
oversubscriptions
If demand for New Shares were to exceed availability,
applicants participating in the Oversubscription Facility will
be subject to scaling on a pro rata basis (by reference to
existing holdings on the Record Date).
Rua reserves the right to place any subsequent shortfall in
accordance with the NZX Listing Rules.
2 of 3
Rights entitlement ratio (for example 1
Right issued for 3 existing shares
held)
Rights
Issued
1
For
Existing Shares
Held
3
Rights exercise ratio
1 Right will exercise to: 1 Ordinary Share
Number of Rights to be issued in the
Rights Issue
113,147,235
Treatment of fractions** Where fractions arise in the calculation of rights, they will
be rounded down to the nearest right
Subscription price
The price payable per equity security upon exercise
of rights to subscribe for new shares under the rights
issue
$0.025
Letters of entitlement mailed Wednesday, 30/09/2026
Offer open Wednesday, 30/09/2026
Offer close Thursday, 15/10/2026
Quotation date
1
(if Rights or
entitlements will be quoted)
Market open on:
Monday, 28/09/2026
Allotment date Market open on:
Wednesday, 21/10/2026
Section 8: Lead Manager and Underwriter
Lead Manager(s) appointed Y
Name of Lead Manager(s) Northington Partners Limited
Fees, commission or other
consideration payable to Lead
Manager(s) for acting as lead
manager(s)
Rua agrees to pay a lead management fee of 7.5% of the total
gross proceeds raised under the rights offer.
Underwritten N
Name of Underwriter(s) N/A
Extent of underwriting (i.e.
amount or proportion of the offer
that is underwritten)
N/A
Fees, commission or other
consideration payable to
Underwriter(s) for acting as
underwriter(s)
N/A
Summary of significant events
that could lead to the
underwriting being terminated
N/A
1
The Quotation date for Rights will usually be the Ex Date (Listing Rule 4.17.6(b)).
3 of 3
Section 9: Authority for this announcement
Name of person authorised to make
this announcement
Paul Naske
Contact person for this
announcement
Paul Naske
Contact phone number 021 445 154
Contact email address paul.naske@ruabio.com
Date of release through MAP 22/09/2026
---
CLEANSING STATEMENT
22 September 2026
NZX Limited
Wellington 6011
New Zealand
RUA BIOSCIENCE LIMITED (NZX: RUA): NOTICE PURSUANT TO CLAUSE 20(1)(a) OF
SCHEDULE 8 TO THE FINANCIAL MARKETS CONDUCT REGULATIONS 2014
1. Rua Bioscience Limited (NZX: Rua) (Rua) has today announced that it will undertake
a pro rata 1 for 3 renounceable rights offer of fully paid ordinary shares of the same
class as already quoted on the NZX Main Board operated by NZX Limited (
Rights
Offer) and may also seek to privately place any shortfall in the rights issue (Shortfall
Offer, and together with the Rights Offer, the Offers). The Company is seeking to
raise up to NZ$2,828,681 in connection with the Offers.
2. Offers made under the Rights Offer will be made to investors in New Zealand in
reliance upon the exclusion in clause 19 of Schedule 1 to the Financial Markets
Conduct Act 2013 (
FMCA). The Offers made under any Shortfall Offer will be made
to either
wholesale investors or close business associates (within the meaning of
clause 3(2) or clause 4(2), as applicable, of the FMCA), or to investors in New Zealand
in reliance upon the exclusion in clause 19 of Schedule 1 to the FMCA.
3. Offers under the Rights Offer are also being made to investors in Australia in reliance
on the Australian Securities and Investments Commission Corporations (Foreign
Rights Issues) Instrument 2015/356 or otherwise to persons to whom the Offers can
be made without a full disclosure document under Chapter 6D of the Corporations
Act 2001 (Cth).
4. This notice is provided pursuant to clause 20(1)(a) of Schedule 8 to the Financial
Markets Conduct Regulations 2014 (
FMC Regulations).
5. As at the date of this notice:
5.1. Rua is in compliance with the continuous disclosure obligations that apply to it
in relation to Rua’s quoted ordinary shares;
5.2. Rua is in compliance with its “financial reporting obligations” (as defined in
clause 20(5) of Schedule 8 to the FMC Regulations); and
5.3. there is no information that is “excluded information” (as defined in clause 20(5)
of Schedule 8 to the FMC Regulations) in respect of Rua.
6. The Offers are not expected to have any effect on the “control” (as defined in clause
48 of Schedule 1 to the FMCA) of Rua.
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
Paul.naske@ruabio.com
+64 21 445154
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.